Salinomycin sodium salt

Cat. No.: HY-17439
CAS No.: 55721-31-8
Molecular Formula: C₄₂H₆₉NaO₁₁
Molecular Weight: 772.98
Target: Bacterial
Pathway: Anti-infection
Storage: Powder -20°C 3 years
         4°C  2 years
         In solvent -80°C 6 months
         -20°C 1 month
Solubility: DMSO: ≥ 15 mg/mL
          * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

PREPARING STOCK SOLUTIONS

<table>
<thead>
<tr>
<th>Volume Concentration</th>
<th>Mass</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>1.2937 mL</td>
<td>6.4685 mL</td>
<td>12.9369 mL</td>
<td></td>
</tr>
<tr>
<td>5 mM</td>
<td>0.2587 mL</td>
<td>1.2937 mL</td>
<td>2.5874 mL</td>
<td></td>
</tr>
<tr>
<td>10 mM</td>
<td>0.1294 mL</td>
<td>0.6468 mL</td>
<td>1.2937 mL</td>
<td></td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description: Salinomycin sodium salt, a polyether antibiotic, is identified as a potent anticancer agent.

In Vitro: Salinomycin (0.1-8 µM) inhibits the growth of HUVECs in a dose-dependent manner, accounting for 32.1 and 59.2% inhibition at 4 and 8 µM, respectively. HUVECs exposed to 2, 4 and 8 µM of Salinomycin for 48 h show a dose-dependent reduction in cell number and a change in cell morphology. Salinomycin (4 µM) treatment effectively inhibits HUVEC migration and invasion, and significantly disrupts the capillary-like tube formation of HUVECs. Salinomycin significantly suppresses the expression levels of phosphorylated (p)-FAK in a time- and dose-dependent manner in HUVECs. Salinomycin inhibits HUVEC angiogenesis by disturbing the VEGF-VEGFR2-AKT signaling axis[1]. Combination of RSVL and Salinomycin synergistically inhibits the proliferation of TNBC (MDA-MB-231) cells. RSVL and Salinomycin effectively reduce wound healing, colony and tumorosphere forming capability in TNBC cells. Synergistic combination of RSVL and Salinomycin induces apoptosis in both culture conditions by significant upregulation of Bax with decreased Bcl-2 expression as comparison to untreated and alone drug treatments[2]. Salinomycin (0, 2, 4, 8 and 16 µM) significantly inhibits the proliferation of A2780 and SK-OV-3 cell lines in a dose- and time-dependent manner, (IC₅₀ 24h: 13.8 µM, IC₅₀ 48h: 6.888 µM and IC₅₀ 72h: 4.382 µM for A2780 cell lines), (IC₅₀ 24h: 12.7 µM, IC₅₀ 48h: 9.869 µM and IC₅₀ 72h: 5.022 µM for SK-OV-3 cell lines). Salinomycin blocks the Wnt/β-catenin
pathway in EOC cells\cite{3}. Salinomycin (2 μM) reduces cancer cell proliferation, inhibits STAT3 phosphorylation and P38 and β-catenin expressions, and suppresses epithelial-mesenchymal transition in colorectal cancer cells. Salinomycin (1-5 μM) inhibits cancer cell proliferation and STAT3 signaling in colorectal cancer cells. Furthermore, Salinomycin activates Akt (Ser 473) and down-regulates Hsp27 (Ser 82) phosphorylation in HT-29 and SW480. Salinomycin down-regulates hTERT and reduces telomerase activity when combined with telomerase inhibitor\cite{4}.

**In Vivo**

Salinomycin (5 and 10 mg/kg) significantly suppresses the average tumor volume and tumor weight. Salinomycin hinders the U251 human glioma cell growth in vivo via inhibition of angiogenesis with involvement of AKT and FAK dephosphorylation\cite{1}. Salinomycin (0.5 mg/kg b.wt.) enhances the mean survival time of the tumor bearing Swiss albino mice\cite{2}.

**PROTOCOL**

**Cell Assay**\cite{1}

The effect of Salinomycin on HUVEC growth is determined by MTT assay. Briefly, HUVECs (6,000 cells/well) are seeded in 96-well culture plates for 24 h and incubated with different concentrations of Salinomycin. In the preliminary experiments, Salinomycin treatment for 12, 24, 48 and 72 h shows time-dependent effects on cell growth inhibition. However, treatment for 48 h is the optimal time and is selected for further mechanism evaluation. After Salinomycin treatment for 48 h, 20 μL/well of MTT solution (5 mg/mL) is added and incubated for 5 h. The medium is aspirated and replaced with 200 μL/well of DMSO to dissolve the formazan Salinomycin formed. The color intensity of the formazan solution is measured at 570 nm by a microplate spectrophotometer. The cell viability is expressed as % of the control (as 100%).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**Animal Administration**\cite{1}

Human glioma U251 cells (1×10^7) suspended in 100 μL PBS are injected into the right lower hind flank of each 6-week-old male nude mouse. The mice are then randomly assigned into three groups of 10 mice in each group. After one week, Salinomycin (5 and 10 mg/kg) is administered into the caudal vein every other day for 16 days. Control mice receive an equal volume of vehicle (Salinomycinine) only. Body weight and tumor volume are monitored every two days. At the end of the experiments, tumors are excised, photographed, and weighed. Tumors from each group are used for western blotting and immunohistochemical (IHC) assay.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**CUSTOMER VALIDATION**


See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

**REFERENCES**


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898       Fax: 609-228-5909       E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA